Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.47 |
| ▸ | CHRNG | P07510 | 1/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | CHRND | Q07001 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19250212 | 0.84 | SLC6A2 (0.55) | CYP2B6SLC6A2CHRNA1CHRNGITGA5 | |
| SCHEMBL5925977 | 0.76 | PARP1 (0.57) | CYP2B6SLC6A2CHRNA1CHRNGITGA5 | |
| SCHEMBL15478523 | 0.74 | CYP2B6 (0.80) | CYP2B6SLC6A2CHRNA1CHRNGITGA5 | |
| SCHEMBL7637167 | 0.74 | PARP1 (0.55) | CYP2B6SLC6A2CHRNA1CHRNGITGA5 | |
| SCHEMBL4741237 | 0.74 | PARP1 (0.55) | CYP2B6SLC6A2CHRNA1CHRNGITGA5 | |
| SCHEMBL19250210 | 0.73 | SLC6A2 (0.52) | CYP2B6SLC6A2CHRNA1CHRNGITGA5 | |
| SCHEMBL19250272 | 0.73 | SLC6A2 (0.52) | CYP2B6SLC6A2CHRNA1CHRNGITGA5 | |
| SCHEMBL19250351 | 0.73 | SLC6A2 (0.52) | CYP2B6SLC6A2CHRNA1CHRNGITGA5 | |
| SCHEMBL28632055 | 0.73 | PARP1 (0.53) | CYP2B6SLC6A2CHRNA1CHRNGITGA5 | |
| SCHEMBL111125 | 0.72 | ACHE (0.58) | SLC6A2CHRNA1CHRNGITGA5CHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213023-A1 | METHODS OF TREATING NEUROLOGICAL AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION | AXSOME THERAPEUTICS, INC. | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213023-A1 | METHODS OF TREATING NEUROLOGICAL AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION | DBH, HSD3B1, HSD3B2 | CYP2B6 28/4885SLC6A2 38/4885CHRNA1 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.